<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772705</url>
  </required_header>
  <id_info>
    <org_study_id>2016-92</org_study_id>
    <nct_id>NCT02772705</nct_id>
  </id_info>
  <brief_title>Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans</brief_title>
  <official_title>Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Panyu Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the capacity of standardized uptake value (SUV)
      using single-photo emission computed tomography and computed tomography (SPECT/CT) in
      diagnosing Grave's Disease (hyperthyroidism).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally it is considered that only positron emission tomography(PET) has the ability to
      obtain standardized uptake value（SUV）while single-photo emission computed tomography(SPECT)
      does not have. Recently with the developing of technology, the ability of SPECT has been
      extended.

      On the other hand, thyroid imaging by SPECT can only play an auxiliary role in
      hyperthyroidism diagnosis mainly since it is regarded as nonquantitative. So the
      investigators design this study to search the capacity and accuracy of SUV provided by SPECT
      and CT(CT is used for reconstruction algorithm) in diagnosing GD.

      This is a multiple-center study containing nine groups in China that use GE Discovery NM/CT,
      an advanced equipment. Thus, the data can be more accurate and more available.

      And this is a perspective clinical trial, taking about eight months. The investigators plan
      to evaluate at least 50 Grave's Disease(GD) patients and 50 normal humans as contrast in all.

      Every GD patient must have been diagnosed and the results of thyroid function tests(such as
      TSH,FT3,FT4） must be available. If necessary, the patient's rate of iodine uptake should also
      be known before he/she being included in this study. As for normal people, the results of
      thyroid function tests should be within the range of normal value.

      The data of each participant will be gathered and stored. And the data processing will be
      done with the help of GE staff, using the software Q.Metrix to get the value of SUVmean,
      SUVmax. Finally T test will be used in comparison of the differences.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The thyroid imaging of GD patients and normal humans by SPECT/CT</measure>
    <time_frame>a single point in time, at subject enrollment</time_frame>
    <description>For GD patients and normal healthy volunteers, we will get the data of thyroid fusion imaging by giving them a SPECT/CT check at subject enrollment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The SUV values of GD patients and normal humans provided by Q.Metrix</measure>
    <time_frame>a single point in time, at subject enrollment</time_frame>
    <description>The data of thyroid fusion imaging will be processed by the software, Q.Metrix, which can get the accurate SUV by compensating for photon absorption within the body, removing scattered radiation and etc.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hyperthyroidism</condition>
  <condition>Tomography</condition>
  <condition>Emission-Computed</condition>
  <condition>Single-Photon</condition>
  <arm_group>
    <arm_group_label>Hyperthyroidism</arm_group_label>
    <description>Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Humans</arm_group_label>
    <description>Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        As for GD patients, the study samples will be chosen from the patients in every medical
        center which participates in this study. And they will be chosen before their treatment.

        For the normal humans, they are healthy volunteers without thyroid disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For Group of GD Patients:

        Inclusion Criteria:

          -  certainly diagnosed with GD

          -  no treatment

          -  sign a informed consent

        Exclusion Criteria:

          -  Inflammatory Hyperthyroidism

          -  Secondary Hyperthyroidism (since of medicine, thyrotrophs neoplasms and etc)

          -  Can not finish the check of SPECT/CT

          -  Refuse to sign a informed consent

        For Group of Normal Humans:

        Inclusion Criteria:

          -  without GD

          -  Adult

          -  sign a reformed consent

        Exclusion Criteria:

          -  Without normal values of TSH, FT3, FT4

          -  Can not finish the check of SPECT/CT

          -  Failed to sign a reformed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Li, Master</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital of Sichuan University, Department of Nuclear Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaohong Ou, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>West China Hospital of Sichuan University, Department of Nuclear Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yahao Li, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital of Sichuan University, Department of Nuclear Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yahao Li, Bachelor</last_name>
    <phone>+86 18080141841</phone>
    <email>617381606@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Li, Master</last_name>
    <phone>+86 13881833145</phone>
    <email>lilinhuaxi@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Li, PH.D</last_name>
      <phone>+86 18811612193</phone>
      <email>Lee_mei_bj@sina.com</email>
    </contact>
    <investigator>
      <last_name>Mei Li, PH.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Panyu Central Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Huang</last_name>
      <phone>+86 13719231991</phone>
      <email>13719231991@126.com</email>
    </contact>
    <investigator>
      <last_name>Yi Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanzhu Bian, PH.D</last_name>
      <phone>+86 13073129364</phone>
      <email>yanzhubian99@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanzhu Bian, PH.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingmin Han</last_name>
      <phone>+86 13838178090</phone>
      <email>xmhan@zzu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xingmin Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Inner Mongolia Autonomous Region</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juzhen Liu</last_name>
      <phone>+86 13604718831</phone>
      <email>1053525934@qq.com</email>
    </contact>
    <investigator>
      <last_name>Juzhen Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fourth Military Medical Universit</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoquan Li, PH.D</last_name>
      <phone>+86 15809252822</phone>
      <email>lgqby@sina.com</email>
    </contact>
    <investigator>
      <last_name>Guoquan Li, PH.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Li, Master</last_name>
      <phone>+86 13881833145</phone>
      <email>lilinhuaxi@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yahao Li, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Dong, Master</last_name>
      <phone>+86 13502116364</phone>
      <email>Dongfeng1105@sina.com</email>
    </contact>
    <investigator>
      <last_name>Feng Dong, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linfa Li</last_name>
      <phone>+86 13666670158</phone>
      <email>pet-ct001@163.com</email>
    </contact>
    <investigator>
      <last_name>Linfa Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013 Jan;54(1):83-9. doi: 10.2967/jnumed.112.111476. Review.</citation>
    <PMID>23283563</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Li Yuhao</investigator_full_name>
    <investigator_title>Technologist, a graduated student of Department of Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>Standardized Uptake Value</keyword>
  <keyword>Diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data of the subjects will be shared including gender, age, values of SUV, TSH, FT3, FT4 and other relative records.
The information will not be shared until the study is completed and the article is published.
Anyone who wants to get the data should send an e-mail to Li, with reasons for needing these data.
E-mail address: 617381606@qq.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

